Townsquare Capital LLC Lowers Stock Position in Omeros Co. (NASDAQ:OMER)

Townsquare Capital LLC lowered its position in Omeros Co. (NASDAQ:OMER) by 34.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,383 shares of the biopharmaceutical company’s stock after selling 6,458 shares during the period. Townsquare Capital LLC’s holdings in Omeros were worth $49,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. SPC Financial Inc. bought a new position in Omeros during the third quarter valued at about $77,000. SG Americas Securities LLC bought a new position in Omeros during the third quarter valued at about $80,000. AQR Capital Management LLC bought a new position in Omeros during the second quarter valued at about $105,000. Finally, Comerica Bank grew its position in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on OMER shares. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Omeros presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Omeros Stock Performance

OMER stock opened at $11.61 on Monday. The company has a market capitalization of $672.80 million, a PE ratio of -5.03 and a beta of 1.97. Omeros Co. has a one year low of $2.37 and a one year high of $12.65. The company’s 50 day moving average price is $6.05 and its two-hundred day moving average price is $4.81.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.